Journal of Molecular and Cellular Cardiology
Volume 49, Issue 4 , Pages 625-638 , October 2010

Benfotiamine improves functional recovery of the infarcted heart via activation of pro-survival G6PD/Akt signaling pathway and modulation of neurohormonal response

Received 9 March 2010 ,Revised 19 May 2010 ,Accepted 31 May 2010.

References 

  1. Granger CB, Califf RM, Young S, Candela R, Samaha J, Worley S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Am Coll Cardiol. Mar 15 1993;21(4):920–925
  2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. Jul 23 1998;339(4):229–234
  3. Ashfaq S, Ghazzal Z, Douglas JS, Morris DC, Veledar E, Weintraub WS. Impact of diabetes on five-year outcomes after vein graft interventions performed prior to the drug-eluting stent era. J Invasive Cardiol. Mar 2006;18(3):100–105
  4. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. Jama. Mar 23 2005;293(12):1501–1508
  5. Stone PH, Muller JE, Hartwell T, York BJ, Rutherford JD, Parker CB, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS Study Group. J Am Coll Cardiol. Jul 1989;14(1):49–57
  6. Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Kurisu S, Nishioka K, et al. Impact of acute hyperglycemia on left ventricular function after reperfusion therapy in patients with a first anterior wall acute myocardial infarction. Am Heart J. Oct 2003;146(4):674–678
  7. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. Feb 21 2006;47(4):693–700
  8. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. Mar 17 2006;98(5):596–605
  9. Jain M, Brenner DA, Cui L, Lim CC, Wang B, Pimentel DR, et al. Glucose-6-phosphate dehydrogenase modulates cytosolic redox status and contractile phenotype in adult cardiomyocytes. Circ Res. Jul 25 2003;93(2):e9–e16
  10. Leopold JA, Walker J, Scribner AW, Voetsch B, Zhang YY, Loscalzo AJ, et al. Glucose-6-phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J Biol Chem. Aug 22 2003;278(34):32100–32106
  11. Pan S, World CJ, Kovacs CJ, Berk BC. Glucose 6-phosphate dehydrogenase is regulated through c-Src-mediated tyrosine phosphorylation in endothelial cells. Arterioscler Thromb Vasc Biol. Jun 2009;29(6):895–901
  12. Xu Y, Osborne BW, Stanton RC. Diabetes causes inhibition of glucose-6-phosphate dehydrogenase via activation of PKA, which contributes to oxidative stress in rat kidney cortex. Am J Physiol Ren Physiol. Nov 2005;289(5):F1040–F1047
  13. Zhang Z, Apse K, Pang J, Stanton RC. High glucose inhibits glucose-6-phosphate dehydrogenase via cAMP in aortic endothelial cells. J Biol Chem. Dec 22 2000;275(51):40042–40047
  14. Jain M, Cui L, Brenner DA, Wang B, Handy DE, Leopold JA, et al. Increased myocardial dysfunction after ischemia–reperfusion in mice lacking glucose-6-phosphate dehydrogenase. Circulation. Feb 24 2004;109(7):898–903
  15. Marchetti V, Menghini R, Rizza S, Vivanti A, Feccia T, Lauro D, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes. Aug 2006;55(8):2231–2237
  16. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem. Jan 2009;320(1–2):149–162
  17. Beltramo E, Berrone E, Tarallo S, Porta M. Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine. Diab/Metab Res Rev. Sep 2009;25(6):566–576
  18. Gadau S, Emanueli C, Van Linthout S, Graiani G, Todaro M, Meloni M, et al. Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. Diabetologia. Feb 2006;49(2):405–420
  19. Katare RG, Caporali A, Oikawa A, Meloni M, Emanueli C, Madeddu P. Vitamin B1 analogue benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1 Mediated survival pathway. Circ Heart Fail. Mar 2010;3(2):294–305
  20. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes. Aug 2003;52(8):2110–2120
  21. de Simone G, Wallerson DC, Volpe M, Devereux RB. Echocardiographic measurement of left ventricular mass and volume in normotensive and hypertensive rats. Necropsy validation. Am J Hypertens. Sep 1990;3(9):688–696
  22. Spillmann F, Graiani G, Van Linthout S, Meloni M, Campesi I, Lagrasta C, et al. Regional and global protective effects of tissue kallikrein gene delivery to the peri-infarct myocardium. Regen Med. Mar 2006;1(2):235–254
  23. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Investig. Oct 2003;112(7):1049–1057
  24. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. Nov 1990;82(5):1730–1736
  25. Takagawa J, Zhang Y, Wong ML, Sievers RE, Kapasi NK, Wang Y, et al. Myocardial infarct size measurement in the mouse chronic infarction model: comparison of area- and length-based approaches. J Appl Physiol. Jun 2007;102(6):2104–2111
  26. Claycomb WC, Lanson NA, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, et al. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA. Mar 17 1998;95(6):2979–2984
  27. White SM, Constantin PE, Claycomb WC. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am J Physiol. Mar 2004;286(3):H823–H829
  28. Muraski JA, Fischer KM, Wu W, Cottage CT, Quijada P, Mason M, et al. Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload. Proc Natl Acad Sci USA. Sep 16 2008;105(37):13889–13894
  29. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. Oct 17 1997;91(2):231–241
  30. Logstrup BB, Hofsten DE, Christophersen TB, Moller JE, Botker HE, Pellikka PA, et al. Influence of abnormal glucose metabolism on coronary microvascular function after a recent myocardial infarction. Jacc. Oct 2009;2(10):1159–1166
  31. Hofsten DE, Logstrup BB, Moller JE, Pellikka PA, Egstrup K. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis. Jacc. May 2009;2(5):592–599
  32. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res. Dec 8 2000;87(12):1123–1132
  33. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes. Jun 2002;51(6):1938–1948
  34. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, et al. Oxidative damage to DNA in diabetes mellitus. Lancet. Feb 17 1996;347(8999):444–445
  35. Jermendy G. Evaluating thiamine deficiency in patients with diabetes. Diab Vasc Dis Res. Sep 2006;3(2):120–121
  36. Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV, Kubyshin VL, Lapshina EA, Bryszewska M, et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur J Pharmacol. Aug 27 2007;569(3):180–187
  37. Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. Jan 5 2008;371(9606):64–74
  38. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, et al. Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med. Dec 2007;13(12):1467–1475
  39. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol. May 2 2005;95(9A):8B–13B
  40. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. Jul 1992;20(1):248–254
  41. Moe GW, Rouleau JL, Charbonneau L, Proulx G, Arnold JM, Hall C, et al. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan. Am Heart J. Apr 2000;139(4):587–595

PII: S0022-2828(10)00233-6

doi: 10.1016/j.yjmcc.2010.05.014

Journal of Molecular and Cellular Cardiology
Volume 49, Issue 4 , Pages 625-638 , October 2010

Article Tools

* Image Usage & Resolution